107. Juvenile idiopathic arthritis Clinical trials / Disease details

Clinical trials : 441 / Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142

61 trials found

diseases per page:

Showing 1 to 10 of 61 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004284-30-DE (EUCTR)	13/02/2020	29/07/2019	Repsonse to Treatment with Canakinumabwithout steroids early after diagnosis of systemic onset juven ...	Effectiveness of Canakinumabfor first line steroid free treatment in systemic onset juvenile idiopat ...	systemic juvenile idiopathic arthritis MedDRA version: 20.0;Level: LLT;Classification code 10079454; ...	Trade Name: Ilaris Product Name: Ilaris	Asklepios Klink Sankt Augustin	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Germany
2	NCT02396212 (ClinicalTrials.gov)	May 7, 2015	25/2/2015	Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA	An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab(ACZ885) Admini ...	Systemic Juvenile Idiopathic Arthritis	Biological: Canakinumab	Novartis Pharmaceuticals	NULL	Completed	2 Years	19 Years	All	19	Phase 3	Japan
3	JPRN-JapicCTI-152865	01/4/2015		Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA	An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab(ACZ885) Admini ...	Systemic Juvenile Idiopathic Arthritis	Intervention name : ACZ885 INN of the intervention : Canakinumab Dosage And administration of the inte ...	Novartis Pharma K.K.	NULL		2	19	BOTH	20	Phase 3	NULL
4	EUCTR2013-004867-29-NL (EUCTR)	23/12/2014	23/09/2014	Study of efficacy and safety of dose reduction or dose interval prolongation of canakinumabin patien ...	An open-label canakinumab(ACZ885) dose reduction or dose interval prolongation efficacy and safety s ...	Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis (SJIA) MedDRA version: 19.1 ...	Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3;Phase 4	United States;Hong Kong;Spain;Turkey;Austria;Russian Federation;Israel;Italy;France;Hungary;Mexico;C ...
5	EUCTR2013-004867-29-DE (EUCTR)	28/11/2014	25/08/2014	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and SafetywIth FIrst-line use of CanakinumabAn op ...	Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis(SJIA) MedDRA version: 19.0; ...	Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3;Phase 4	United States;Hong Kong;Spain;Turkey;Austria;Russian Federation;Israel;Italy;France;Hungary;Mexico;C ...
6	NCT02296424 (ClinicalTrials.gov)	November 17, 2014	10/10/2014	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of CanakinumabAn O ...	Systemic Juvenile Idiopathic Arthritis (SJIA)	Drug: ACZ885 150 mg (Canakinumab)	Novartis Pharmaceuticals	NULL	Completed	2 Years	20 Years	All	182	Phase 3	United States;Austria;Belgium;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;R ...
7	EUCTR2013-004867-29-BE (EUCTR)	07/11/2014	29/09/2014	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and SafetywIth FIrst-line use of CanakinumabAn op ...	Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis(SJIA) MedDRA version: 18.0; ...	Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3;Phase 4	United States;Hong Kong;Spain;Turkey;Austria;Russian Federation;Israel;Italy;France;Hungary;Mexico;C ...
8	EUCTR2013-004867-29-HU (EUCTR)	04/11/2014	25/08/2014	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and SafetywIth FIrst-line use of CanakinumabAn op ...	Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis(SJIA) MedDRA version: 18.0; ...	Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3;Phase 4	United States;Hong Kong;Spain;Turkey;Austria;Russian Federation;Israel;Italy;France;Hungary;Mexico;C ...
9	NCT02334748 (ClinicalTrials.gov)	November 3, 2014	23/12/2014	A Study of Canakinumabin Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic ...	A French Open-label Extension Study of Canakinumabin Patients Who Participated in International Phas ...	Systemic Juvenile Idiopathic Arthritis;Hereditary Periodic Fevers	Drug: canakinumab	Novartis Pharmaceuticals	NULL	Completed	5 Years	20 Years	All	31	Phase 3	France
10	EUCTR2013-004867-29-ES (EUCTR)	20/10/2014	06/08/2014	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line use of Canakinumab	ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and SafetywIth FIrst-line use of CanakinumabAn op ...	Active systemic manifestations of Systemic Juvenile Idiopathic Arthritis(SJIA) MedDRA version: 17.0; ...	Trade Name: Ilaris Product Name: canakinumab Product Code: ACZ885 INN or Proposed INN: CANAKINUMAB	Novartis Farmacéutica, S.A.	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3;Phase 4	United States;Hong Kong;Spain;Turkey;Austria;Russian Federation;Israel;Italy;France;Hungary;Mexico;C ...

First Previous1 2 3 4 5 6 7Next Last